Examkin

Question

Difficulty: HardRheumatology and Immunology

An established clinic patient, a 42-year-old female with known limited cutaneous systemic sclerosis, presents to discuss worsening symptoms in her hands. She describes increasingly frequent and painful episodes where her fingers turn white, then blue, upon exposure to mild temperature drops. The episodes are now significantly limiting her daily activities. Arrange the following management steps in the correct chronological order of therapeutic escalation, starting from initial baseline management and progressing to interventions for critical, medically refractory ischemia.

  1. 1Implement conservative lifestyle modifications, including cold avoidance and smoking cessation.
  2. 2Initiate first-line pharmacotherapy with an oral dihydropyridine calcium channel blocker.
  3. 3Add a phosphodiesterase-5 (PDE-5) inhibitor to the patient's oral regimen.
  4. 4Administer continuous intravenous prostanoids.
  5. 5Perform a localized digital sympathectomy.

Answer

The correct sequence of therapy escalation for Raynaud phenomenon is: lifestyle modifications, followed by oral calcium channel blockers, addition of oral PDE-5 inhibitors, intravenous prostanoids, and finally digital sympathectomy.
The established algorithm for secondary Raynaud phenomenon dictates a progressive escalation. It begins with universally applicable conservative measures. If symptoms persist, first-line oral monotherapy with a calcium channel blocker is initiated. Refractory cases warrant combination oral therapy, often with a PDE-5 inhibitor. When oral options are exhausted and the patient faces critical ischemia or digital ulcers, inpatient treatment with intravenous prostanoids is required. Finally, digital sympathectomy is a salvage procedure for tissue at immediate risk of necrosis despite maximal medical therapy.

Step-by-Step Solution

1
Identify the condition and establish the baseline severity.
The patient has progressively worsening Raynaud phenomenon secondary to systemic sclerosis.
Establishing the severity determines the starting point of the treatment algorithm.
2
Select the initial, non-pharmacologic intervention.
Implement lifestyle modifications.
Conservative measures (keeping warm, avoiding vasoconstrictors) are universally required as the baseline intervention.
3
Determine the first-line pharmacologic agent.
Initiate an oral dihydropyridine calcium channel blocker.
CCBs are the most effective and well-tolerated oral agents for preventing vasospastic episodes.
4
Identify the next step for disease refractory to monotherapy.
Add a PDE-5 inhibitor to the oral regimen.
Combination oral therapy is indicated to maximize vasodilation before progressing to invasive treatments.
5
Select the treatment for severe, impending tissue loss.
Administer intravenous prostanoids.
Parenteral therapy is strictly reserved for critical ischemia or active digital ulcers that fail oral therapy.
6
Determine the final option for medically refractory cases.
Perform a digital sympathectomy.
Surgical intervention is the last resort to restore perfusion and prevent autoamputation.

Key Concept

The stepwise management of secondary Raynaud phenomenon in Systemic Sclerosis escalates sequentially from conservative lifestyle changes to oral monotherapy, combination oral therapy, intravenous therapy, and ultimately surgical intervention.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic